ASCO GU 2019: Questions and lessons moving forward from CARMENA: A medical oncologist’s perspective

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019.

Cytoreductive nephrectomy (CN) is defined as the surgical removal of the primary renal cell carcinoma (RCC) tumour before starting systemic therapy. The following paper from medical oncologist Dr Lauren Harshman, Dana-Farber Cancer Institute, Boston, USA, suggests that this is an exciting era for the systemic treatment of advanced RCC, but there still remains a role for cytoreductive nephrectomy in selected patients.

Read more in UroToday here

Share this Post!


Related post

  TOP